Elisabeth von Guggenberg

Scopus Author ID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 14

Top Venues

Pharmaceuticals (Basel, Switzerland)

Pharmaceutics

Molecules (Basel, Switzerland)

Cancers

Tirol Kliniken

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Tirol Kliniken Apr 23 2001

Austria

Radiopharmacist :: Department of Nuclear Medicine

Publications

Taraneh Sadat Zavvar, Anton Amadeus Hörmann, Maximilian Klingler, Dominik Summer, Christine Rangger, Laurence Desrues, Helene Castel, Pierrick Gandolfo, Elisabeth von Guggenberg
Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs. Pharmaceuticals (Basel, Switzerland) 16 (2) (2023)
Anton Amadeus Hörmann, Maximilian Klingler, Christine Rangger, Christian Mair, Lieke Joosten, Gerben M Franssen, Peter Laverman, Elisabeth von Guggenberg
Effect of N -Terminal Peptide Modifications on In Vitro and In Vivo Properties of 177 Lu-Labeled Peptide Analogs Targeting CCK2R. Pharmaceutics 15 (3) (2023)
Anton Amadeus Hörmann, Maximilian Klingler, Christine Rangger, Christian Mair, Lieke Joosten, Gerben M Franssen, Peter Laverman, Elisabeth von Guggenberg
Effect of N -Terminal Peptide Modifications on In Vitro and In Vivo Properties of 177 Lu-Labeled Peptide Analogs Targeting CCK2R. Pharmaceutics 15 (3) (2023)
Anton Amadeus Hörmann, Maximilian Klingler, Christine Rangger, Christian Mair, Lieke Joosten, Gerben M Franssen, Peter Laverman, Elisabeth von Guggenberg
Effect of N -Terminal Peptide Modifications on In Vitro and In Vivo Properties of 177 Lu-Labeled Peptide Analogs Targeting CCK2R. Pharmaceutics 15 (3) (2023)
Anton Amadeus Hörmann, Elisabeth Plhak, Maximilian Klingler, Christine Rangger, Joachim Pfister, Gert Schwach, Herbert Kvaternik, Elisabeth von Guggenberg
Automated Synthesis of 68 Ga-Labeled DOTA-MGS8 and Preclinical Characterization of Cholecystokinin-2 Receptor Targeting. Molecules (Basel, Switzerland) 27 (6) (2022)
Anton A Hörmann, Maximilian Klingler, Christine Rangger, Christian Mair, Clemens Decristoforo, Christian Uprimny, Irene J Virgolini, Elisabeth von Guggenberg
Radiopharmaceutical Formulation and Preclinical Testing of 68Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial. Pharmaceuticals (Basel, Switzerland) 14 (6) (2021)
Elisabeth von Guggenberg, Petra Kolenc, Christof Rottenburger, Renata Mikolajczak, Alicja Hubalewska-Dydejczyk
Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals. Cancers 13 (22) (2021)
Steffen Bayerschmidt, Christian Uprimny, Alexander Stephan Kroiss, Josef Fritz, Bernhard Nilica, Hanna Svirydenka, Clemens Decristoforo, Elisabeth von Guggenberg, Wolfgang Horninger, Irene Johanna Virgolini
Comparison of Early Imaging and Imaging 60 min Post-Injection after Forced Diuresis with Furosemide in the Assessment of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT. Diagnostics (Basel, Switzerland) 11 (7) (2021)
Maximilian Klingler, Anton A Hörmann, Christine Rangger, Laurence Desrues, Helene Castel, Pierrick Gandolfo, Elisabeth von Guggenberg
Stabilization Strategies for Linear Minigastrin Analogues: Further Improvements via the Inclusion of Proline into the Peptide Sequence. Journal of medicinal chemistry 63 (23) (2020)
Anton Amadeus Hörmann, Maximilian Klingler, Maliheh Rezaeianpour, Nikolas Hörmann, Ronald Gust, Soraya Shahhosseini, Elisabeth von Guggenberg
Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177. Molecules (Basel, Switzerland) 25 (19) (2020)
Maximilian Klingler, Christine Rangger, Dominik Summer, Piriya Kaeopookum, Clemens Decristoforo, Elisabeth von Guggenberg
Correction: Klingler, M., et al. Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m. Pharmaceuticals 2019, 12, 13. Pharmaceuticals (Basel, Switzerland) 12 (2) (2019)
Maximilian Klingler, Christine Rangger, Dominik Summer, Piriya Kaeopookum, Clemens Decristoforo, Elisabeth von Guggenberg
Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m. Pharmaceuticals (Basel, Switzerland) 12 (1) (2019)
Dominik Summer, Andrea Kroess, Rudolf Woerndle, Christine Rangger, Maximilian Klingler, Hubertus Haas, Leopold Kremser, Herbert H Lindner, Elisabeth von Guggenberg, Clemens Decristoforo
Multimerization results in formation of re-bindable metabolites: A proof of concept study with FSC-based minigastrin imaging probes targeting CCK2R expression. PloS one 13 (7) (2018)
Christine Rangger, Maximilian Klingler, Lajos Balogh, Zita Pöstényi, Andras Polyak, Dariusz Pawlak, Renata Mikołajczak, Elisabeth von Guggenberg
177Lu Labeled Cyclic Minigastrin Analogues with Therapeutic Activity in CCK2R Expressing Tumors: Preclinical Evaluation of a Kit Formulation. Molecular pharmaceutics 14 (9) (2017)

Elisabeth von Guggenberg.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Elisabeth von Guggenberg